Refine by
Idiopathic Pulmonary Fibrosis Equipment & Supplies
18 equipment items found
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Mechanism: Porcupine inhibitor. Area under investigation: idiopathic pulmonary fibrosis. Date commenced phase: Q4 2021. Estimated Filing Acceptance: Country US: EU: Japan: China. Additional information: Molecule size: Small molecule. Status change: ...
Manufactured by:Eleven P15 based inDenver, COLORADO (USA)
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and localized to the lung. IPF is a fatal disease with median survival at 3-5 years. Two drugs have been approved for treatment of IPF, but these drugs fail to reverse scarred lung tissue or to ...
by:AdAlta Limited based inBundoora, AUSTRALIA
A specific form of lung fibrosis is Idiopathic pulmonary fibrosis (IPF), which is a chronic and ultimately fatal disease, where tissue deep in the lungs becomes scarred, over time, resulting in a progressive decline in lung function and shortness of breath. There is currently no cure for IPF with most people living only three to ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, irreversible loss of lung function. The average life expectancy after ...
Manufactured by:Lung Therapeutics, Inc. based inAustin, TEXAS (USA)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function. LTI-03 operates through a novel mechanism of action (MOA) that is unlike any MOA seen in the therapeutic candidates of today. ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. Following further development, AdAlta ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon ...
Manufactured by:Newcells Biotech Limited based inNewcastle Upon Tyne, UNITED KINGDOM
Human lung fibroblast model to test the efficacy of anti-fibrotic agents in vitro. Newcells human primary lung fibroblast model is the basis of our FMT assay to evaluate anti-fibrotic therapies in vitro at high throughput. The assay replicates extracellular matrix deposition (ECM) observed in vivo when lung fibroblast injury leads to activation and proliferation. Following injury, pulmonary ...
Manufactured by:Ocean Biomedical based inProvidence, RHODE ISLAND (USA)
New therapeutic antibodies for effective treatment of NSCLC and other disorders. We are moving towards Phase 1 clinical trials of patented antibodies for the treatment of NSCLC. Our lead program, OCX-253 was chosen because it stimulates the B-Raf protooncogene while inhibiting apoptosis, NK cell accumulation and activation, LIM kinase 2, p-cofilin, the tumor suppressor PTEN, and p53. In addition, ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
GLPG1205 is potent, selective and orally active GPR84 (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis[1][2]. GLPG1205 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide ...
Manufactured by:United Therapeutics Corporation based inSilver Spring, MARYLAND (USA)
TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish ...
by:The Regeneration Center based inBangkok, THAILAND
Several clinical studies have clearly demonstrated the benefits of stem cells. Peer-reviewed medical journals today are intent on finding the richest source of stem cells in the human body. Researchers have found that umbilical cord blood is rich in stem cells, which eventually paved the way for researchers to move away from the controversial embryonic stem cells. As a result of these trials, it ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory ...